Compare FSCO & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSCO | LTGO |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2013 | 2026 |
| Metric | FSCO | LTGO |
|---|---|---|
| Price | $5.05 | $14.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $52.25 |
| AVG Volume (30 Days) | ★ 1.1M | 350.0K |
| Earning Date | 05-08-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $13.50 |
| 52 Week High | $6.79 | $25.93 |
| Indicator | FSCO | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 33.81 |
| Support Level | $4.90 | N/A |
| Resistance Level | $5.31 | $16.56 |
| Average True Range (ATR) | 0.11 | 1.21 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 54.55 | 14.06 |
FS Credit Opportunities Corp is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. It predominantly invests in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments. The credit instruments in which it invests are typically rated below investment grade by rating agencies or would be rated below investment grade if rated. To achieve its investment objectives, the fund focuses on strategies such as Opportunistic Credit, Special Situations, and Capital Structure Solutions.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.